Group 1 - The company has received the drug registration certificate for Acetate Atosiban Injection from the National Medical Products Administration, indicating successful approval for domestic production [1][3] - The drug is classified as a Class 4 chemical drug with a shelf life of 18 months and is intended for use in pregnant women with indications for preterm labor, providing a safer option with lower adverse reaction rates compared to other medications [2][3] - The approval of Acetate Atosiban Injection represents a strategic expansion for the company in the field of reproductive medicine, enhancing its market competitiveness and contributing to national population quality development [3] Group 2 - The specific sales performance of the product may be influenced by market demand and sales expansion, leading to uncertainties regarding its short-term impact on the company's operating performance [4]
江苏诺泰澳赛诺生物制药股份有限公司关于自愿披露醋酸阿托西班注射液获得药品注册证书的公告